Long-Term Follow-Up, Association between CARD15/NOD2 Polymorphisms, and Clinical Disease Behavior in Crohn's Disease Surgical Patients.


Journal

Mediators of inflammation
ISSN: 1466-1861
Titre abrégé: Mediators Inflamm
Pays: United States
ID NLM: 9209001

Informations de publication

Date de publication:
2021
Historique:
received: 18 09 2020
revised: 04 02 2021
accepted: 08 02 2021
entrez: 12 3 2021
pubmed: 13 3 2021
medline: 5 11 2021
Statut: epublish

Résumé

CARD15/NOD2 is the most significant genetic susceptibility in Crohn's disease (CD) even though a relationship between the different polymorphisms and clinical phenotype has not been described yet. The study is aimed at analyzing, in a group of CD patients undergoing surgery, the relationship between CARD15/NOD2 polymorphisms and the clinical CD behavior after a long-term follow-up, in order to identify potential clinical biomarkers of prognosis. 191 surgical CD patients were prospectively characterized both for the main single nucleotide polymorphisms of CARD15/NOD2 and for many other environmental risk factors connected with the severe disease form. After a mean follow-up of 7.3 years, the correlations between clinical features and CD natural history were analyzed. CARD15/NOD2 polymorphisms were significantly associated with younger age at diagnosis compared to wild type cases ( 3020insC CARD15 polymorphism is associated with an earlier CD onset, and age at CD diagnosis < 27 years was confirmed to have a detrimental effect on its clinical course. In addition, the familiarity seems to be connected with a more aggressive postoperative course. Finally, for the first time, we have observed a lower rate of responsiveness to azathioprine in patients carrying an hz881 and a 3020insC.

Sections du résumé

BACKGROUND BACKGROUND
CARD15/NOD2 is the most significant genetic susceptibility in Crohn's disease (CD) even though a relationship between the different polymorphisms and clinical phenotype has not been described yet. The study is aimed at analyzing, in a group of CD patients undergoing surgery, the relationship between CARD15/NOD2 polymorphisms and the clinical CD behavior after a long-term follow-up, in order to identify potential clinical biomarkers of prognosis.
METHODS METHODS
191 surgical CD patients were prospectively characterized both for the main single nucleotide polymorphisms of CARD15/NOD2 and for many other environmental risk factors connected with the severe disease form. After a mean follow-up of 7.3 years, the correlations between clinical features and CD natural history were analyzed.
RESULTS RESULTS
CARD15/NOD2 polymorphisms were significantly associated with younger age at diagnosis compared to wild type cases (
CONCLUSIONS CONCLUSIONS
3020insC CARD15 polymorphism is associated with an earlier CD onset, and age at CD diagnosis < 27 years was confirmed to have a detrimental effect on its clinical course. In addition, the familiarity seems to be connected with a more aggressive postoperative course. Finally, for the first time, we have observed a lower rate of responsiveness to azathioprine in patients carrying an hz881 and a 3020insC.

Identifiants

pubmed: 33708009
doi: 10.1155/2021/8854916
pmc: PMC7932801
doi:

Substances chimiques

NOD2 protein, human 0
Nod2 Signaling Adaptor Protein 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

8854916

Informations de copyright

Copyright © 2021 Francesco Giudici et al.

Déclaration de conflit d'intérêts

The authors declare that they have no competing interests.

Références

Gut. 2007 Oct;56(10):1387-92
pubmed: 17494106
Inflamm Bowel Dis. 2011 Jan;17(1):6-12
pubmed: 20848478
Food Nutr Res. 2013 Apr 12;57:
pubmed: 23589711
Bosn J Basic Med Sci. 2015 May 25;15(2):67-72
pubmed: 26042516
Gut. 2004 Feb;53(2):246-50
pubmed: 14724158
Gastroenterology. 2001 Apr;120(5):1093-9
pubmed: 11266373
Am J Gastroenterol. 2010 Dec;105(12):2610-6
pubmed: 20700115
Nat Immunol. 2004 Aug;5(8):800-8
pubmed: 15220916
Pediatrics. 2012 Oct;130(4):e794-803
pubmed: 23008454
Eur J Gastroenterol Hepatol. 2008 Jan;20(1):37-45
pubmed: 18090989
J Crohns Colitis. 2013 May;7(4):280-5
pubmed: 22537639
Clin Gastroenterol Hepatol. 2004 Nov;2(11):1003-9
pubmed: 15551253
Nature. 2012 Nov 1;491(7422):119-24
pubmed: 23128233
J Crohns Colitis. 2014 Jul;8(7):607-16
pubmed: 24315795
Gut. 2002 Dec;51(6):808-13
pubmed: 12427781
Int J Exp Pathol. 1991 Feb;72(1):1-7
pubmed: 1888662
Inflamm Bowel Dis. 2012 Jun;18(6):1101-11
pubmed: 21987436
Nature. 2001 May 31;411(6837):603-6
pubmed: 11385577
Am J Gastroenterol. 2014 Mar;109(3):395-400
pubmed: 24419484
Aliment Pharmacol Ther. 2011 Dec;34(11-12):1351
pubmed: 22085379
Ann Intern Med. 2012 Mar 6;156(5):350-9
pubmed: 22393130
Am J Gastroenterol. 2007 Aug;102(8):1692-701
pubmed: 17555460
Proc Natl Acad Sci U S A. 2005 Dec 13;102(50):18129-34
pubmed: 16330776
J Pharmacol Exp Ther. 2013 Jan;344(1):207-17
pubmed: 23115221
Inflamm Bowel Dis. 2013 Apr;19(5):1010-7
pubmed: 23399739
Nature. 2007 Jul 26;448(7152):427-34
pubmed: 17653185
Gastroenterology. 1996 Feb;110(2):424-31
pubmed: 8566589
Gut. 1991 Sep;32(9):1016-9
pubmed: 1916482
Nature. 2001 May 31;411(6837):599-603
pubmed: 11385576
World J Gastroenterol. 2014 May 7;20(17):5008-16
pubmed: 24803813
Am J Gastroenterol. 2010 Dec;105(12):2687-92
pubmed: 20940708
Gastroenterology. 1986 Dec;91(6):1396-400
pubmed: 3770366
Clin Sci (Lond). 1996 Sep;91(3):359-64
pubmed: 8869420
Am J Clin Nutr. 2004 Nov;80(5):1342-52
pubmed: 15531685
Gut. 2013 Apr;62(4):630-49
pubmed: 23335431
Gastroenterology. 2010 Nov;139(5):1630-41, 1641.e1-2
pubmed: 20637199
Can J Gastroenterol. 2012 Dec;26(12):909-15
pubmed: 23248794
Biomed Res Int. 2013;2013:435268
pubmed: 23991417
World J Gastroenterol. 2011 Jun 14;17(22):2740-7
pubmed: 21734782
Gastroenterology. 1996 Sep;111(3):597-603
pubmed: 8780562
PLoS One. 2011;6(9):e24715
pubmed: 21931826
Inflamm Bowel Dis. 2012 May;18(5):889-99
pubmed: 22021194
Inflamm Bowel Dis. 2002 Nov;8(6):390-8
pubmed: 12454614
Nestle Nutr Workshop Ser Pediatr Program. 2008;61:145-81
pubmed: 18196951
World J Gastroenterol. 2013 Jul 28;19(28):4447-54
pubmed: 23901219
Dig Dis Sci. 2001 Aug;46(8):1717-21
pubmed: 11508673
World J Gastroenterol. 2014 Feb 7;20(5):1238-47
pubmed: 24574798
Scand J Gastroenterol. 2010 Dec;45(12):1464-71
pubmed: 20704469
Eur J Gastroenterol Hepatol. 1996 Mar;8(3):225-8
pubmed: 8724021
Inflamm Bowel Dis. 2013 Feb;19(2):445-56
pubmed: 22573536
Int J Epidemiol. 1998 Jun;27(3):397-404
pubmed: 9698126
Am J Hum Genet. 2002 Apr;70(4):845-57
pubmed: 11875755
Inflamm Bowel Dis. 2007 Apr;13(4):431-8
pubmed: 17206676
Aliment Pharmacol Ther. 2002 Jan;16(1):51-60
pubmed: 11856078
Pediatrics. 2007 Aug;120(2):354-61
pubmed: 17671062
Am J Gastroenterol. 2005 Jan;100(1):84-92
pubmed: 15654786
Am J Gastroenterol. 2000 Aug;95(8):1949-54
pubmed: 10950041
Aliment Pharmacol Ther. 2003 Mar 15;17(6):817-25
pubmed: 12641504
Gastroenterology. 2013 Aug;145(2):293-308
pubmed: 23751777
Aliment Pharmacol Ther. 2000 Nov;14(11):1429-34
pubmed: 11069313
Science. 2005 Jun 10;308(5728):1635-8
pubmed: 15831718
Dig Surg. 2012;29(2):107-14
pubmed: 22440928

Auteurs

Francesco Giudici (F)

Department of Clinical and Experimental Medicine, Surgical Unit, University of Florence, Italy.

Tiziana Cavalli (T)

Department of Clinical and Experimental Medicine, Surgical Unit, University of Florence, Italy.

Cristina Luceri (C)

Department of Neuroscience, Psychology, Pharmacology and Child Health (NEUROFARBA), Italy.

Edda Russo (E)

Department of Clinical and Experimental Medicine, Surgical Unit, University of Florence, Italy.

Daniela Zambonin (D)

Department of Clinical and Experimental Medicine, Surgical Unit, University of Florence, Italy.

Stefano Scaringi (S)

Department of Clinical and Experimental Medicine, Surgical Unit, University of Florence, Italy.

Ferdinando Ficari (F)

Department of Clinical and Experimental Medicine, Surgical Unit, University of Florence, Italy.

Marilena Fazi (M)

Department of Clinical and Experimental Medicine, Surgical Unit, University of Florence, Italy.

Amedeo Amedei (A)

Department of Clinical and Experimental Medicine, Surgical Unit, University of Florence, Italy.

Francesco Tonelli (F)

Department of Clinical and Experimental Medicine, Surgical Unit, University of Florence, Italy.

Cecilia Malentacchi (C)

Department of Biomedical Experimental and Clinical Sciences, "Mario Serio", Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH